These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1658976)

  • 1. [Antiarrhythmic agents. Receptor hypothesis explains mechanisms of action].
    Bjørnstad H; Refsum H
    Tidsskr Nor Laegeforen; 1991 Oct; 111(26):3187-9. PubMed ID: 1658976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
    Antoni H; Weirich J
    Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of action of class III anti-arrhythmia agents].
    Adamantidis MM
    Arch Mal Coeur Vaiss; 1995 Jan; 88 Spec No 1():33-40. PubMed ID: 7786143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New perspectives in cardiology: pharmacodynamic classification of antiarrhythmic drugs.
    Adams HR
    J Am Vet Med Assoc; 1986 Sep; 189(5):525-32. PubMed ID: 2875984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New aspects of the molecular effect of anti-arrhythmia agents].
    Honerjäger P
    Herz; 1990 Apr; 15(2):70-8. PubMed ID: 2160907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaughan Williams class IV antiarrhythmic drugs].
    Horie M; Washizuka T; Ikeguchi S; Sasayama S
    Nihon Rinsho; 1996 Aug; 54(8):2132-7. PubMed ID: 8810788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
    Aupetit JF; Bui-Xuan B; Kioueh I; Loufoua J; Frassati D; Timour Q
    Can J Physiol Pharmacol; 2000 Mar; 78(3):208-16. PubMed ID: 10721812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Principles for the classification of anti-arrhythmia agents in cardiac arrhythmias].
    Ravens U
    Z Kardiol; 1992; 81 Suppl 4():119-25. PubMed ID: 1290288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blockers as antiarrhythmic agents.
    Zicha S; Tsuji Y; Shiroshita-Takeshita A; Nattel S
    Handb Exp Pharmacol; 2006; (171):235-66. PubMed ID: 16610347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification and mechanism of action of antiarrhythmic drugs.
    Scholz H
    Fundam Clin Pharmacol; 1994; 8(5):385-90. PubMed ID: 7875632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class III antiarrhythmic action linked with positive inotropy: antiarrhythmic, electrophysiological, and hemodynamic effects of the sea-anemone polypeptide ATX II in the dog heart in situ.
    Platou ES; Refsum H; Hotvedt R
    J Cardiovasc Pharmacol; 1986; 8(3):459-65. PubMed ID: 2425158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of negative inotropic and antiarrhythmic effects of class 1 antiarrhythmic drugs.
    Nawada T; Tanaka Y; Hirai S; Hisatome I; Hasegawa J; Kotake H; Mashiba H
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):347-55. PubMed ID: 7952796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-arrhythmic and cardiodepressive effects of anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1988; 77 Suppl 5():113-9. PubMed ID: 2464875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New aspects of frequency-dependent effect of class 1 anti-arrhythmia drugs. A critical analysis of useful subclassification].
    Weirich J; Antoni H
    Z Kardiol; 1991 Mar; 80(3):177-86. PubMed ID: 2058249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voltage- and rate-dependent depression of Vmax of action potentials by a new antiarrhythmic agent, E-0747, in swine cardiac Purkinje fibers.
    Sawada K; Shoji T; Igarashi T; Hiraoka M
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):51-6. PubMed ID: 2434794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of class III antiarrhythmic agents.
    Hondeghem LM
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S17-22. PubMed ID: 1279304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of the novel III class anti-arrhythmia preparation (AL-275) in experimental myocardium and sympathetic stimulation].
    Kaverina NV; Lyskovtsev VV; Kishchuk EP
    Eksp Klin Farmakol; 2001; 64(1):33-7. PubMed ID: 11544801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.